Joanne Kennedy

Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy.

Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy.

Dickkopf-related protein 2 (DKK2)is a member of the Dickkopf household in Wnt signaling pathway. Recently, we discovered that antibodies against DKK2 might activate pure killer (NK) and CD8+ T cells in tumors and inhibit tumor progress. In this paper, we report the rational design of peptides for identification of linear epitopes and generation of neutralizing …

Rational design of peptides for identification of linear epitopes and generation of neutralizing monoclonal antibodies against DKK2 for cancer therapy. Read More »

Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer.

Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer.

Operable gastrointestinal cancers proceed to pose vital challenges. Radical resections are hardly ever healing, and chemotherapy is ready to cut back tumor recurrence for solely a small proportion of patients. Despite the apparent benefits of extirpation of the identifiable tumor(s), the inflammatory milieu that accompanies surgery and the obligate time off cytotoxic brokers permits for …

Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer. Read More »

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.

SARS-CoV-2-caused COVID-19 instances are rising globally, calling for growing efficient therapeutics to regulate the present pandemic. SARS-CoV-2 and SARS-CoV acknowledge angiotensin-converting enzyme 2 (ACE2) receptor through the receptor-binding area (RBD). Here, we recognized six SARS-CoV RBD-specific neutralizing monoclonal antibodies (nAbs) that cross-reacted with SARS-CoV-2 RBD, two of which, 18F3 and 7B11, neutralized SARS-CoV-2 an infection. …

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Read More »

Mybiosource Polyclonal Antibodies

Find Polyclonal Antibodies from Mybiosource at Gentaur. Submit your order to info@gentaur.com. Cat Name Price 18-AAP-330E BIM/BOD Polyclonal Antibody 345 € 544-MBS9203127 C1QL3 Polyclonal Antibody 270 € 18-SPA-865F Calnexin Polyclonal Antibody 425 € 18-KAP-ST010E Casein Kinase 2 Polyclonal Antibody 322 € 544-MBS8242077 CD115 CSF1R Polyclonal Antibody 369 € 544-MBS926116 CD14 Polyclonal Antibody 391 € 544-MBS176833 CD68 …

Mybiosource Polyclonal Antibodies Read More »

Scroll to Top